glp 1 discovery Reflections on the GLP-1 as a satiety hormone: Implications for obesity therapy and future directions Frontiers | GLP-1 receptor agonists:

They show that GLP-1R agonists can reduce amyloidosis and mitigate Alzheimers disease symptoms in mice by activating AMPK signaling, regulating neuronal amyloid- metabolism and promoting microglial phagocytosis

Obesity is a chronic condition, just like diabetes

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes

The labels address this: the day of weekly administration may be changed if necessary as long as the time between two doses is at least 72 hours

So, 80% breathing